drugset / Trial / NCT04651777

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

NCT04651777

Phase 3 Active not recruiting 31 enrolled Dr. Grace Parraga GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of treatment with triple therapy an inhaler that contains three types of asthma medications, on participants with poorly controlled asthma. The triple therapy medication contains fluticasone furoate, an inhaled corticosteroid (ICS) which reduces inflammation in the lungs; umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), a medication which helps open up the airways; and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA) which also helps open up airways, delivered in a single daily inhalation via an Ellipta inhaler. The Investigators will evaluate lung structure and function using magnetic resonance imaging (MRI). Participants will inhale xenon gas before an MRI image of their lungs is taken. Using a special technique xenon is visible in MRI images, so this lets us see how air spreads in the lungs. In healthy lungs, the gas fills the lungs evenly, but in unhealthy lungs, the gas may fill the lungs unevenly and they will appear patchy. The patchy areas are called ventilation defects. A CT of the chest will be done to assess the structure of the lungs. The Investigators will also be using lung function testing and questionnaires to compare them to MRI ventilation defect measurements.

Timeline

Start
2022-08-08
Primary completion
2023-08-25
Completion
2025-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 200 ug Inhaled
Subject Umeclidinium Other / unclassified 62.5 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled

Indications